Quantcast
Last updated on April 24, 2014 at 1:21 EDT

Aeterna Zentaris: Final Phase 2 Data for Perifosine in Lymphomas to be Presented at Upcoming ASH Meeting

November 26, 2012

QUÉBEC CITY, Nov. 26, 2012 /PRNewswire/ – Aeterna Zentaris Inc. (NASDAQ:
AEZS) (TSX: AEZ) today announced that final Phase 2 data for
perifosine, its oral AKT inhibitor, combined with sorafenib in patients
with relapsed/refractory lymphomas, will be presented at the upcoming
American Society of Hematology (“ASH”) annual meeting in Atlanta,
Georgia, December 8-11, 2012. Data will be disclosed during a poster
presentation by Anna Guidetti, MD, of the Fondazione IRCCS Instituto Nazionale Tumori, Milan, Italy.


    Abstract #3679:       "Dual Targeted Therapy with the AKT Inhibitor
                          Perifosine and the Multikinase Inhibitor
                          Sorafenib in Patients with Relapsed/Refractory
                          Lymphomas: Final Results of a Phase 2 Trial", A
                          Guidetti, S. Viviani, A. Marchiano, A. Dodero, L.
                          Farina, S.L. Locatelli, D. Russo, P. Bulian, R.
                          Sorasio, M. Di Nicola, L. Giordano, P. Corradini,
                          A.M. Gianni, C. Carlo-Stella.

    Poster Session #624:  "Lymphoma-Therapy with Biologic Agents, Excluding
                          Pre-Clinical Models: Poster III"

    Date & Time:          Monday, December 10, 2012, from 6 pm to 8 pm
                          (Eastern) 

    Venue:                Georgia World Congress Center, Hall B1-B2, Level
                          1, Building B

About Perifosine

Perifosine is a novel, oral anticancer treatment that inhibits Akt
activation in the phosphoinositide 3-kinase (PI3K) pathway. It has been
granted orphan drug and orphan medicinal product designations for
multiple myeloma (“MM”) from the FDA and the European Medicines Agency
(“EMA”), respectively. Perifosine has also received Fast Track
designation from the FDA. The ongoing Phase 3 trial in MM is conducted
under a Special Protocol Assessment from the FDA and a positive
Scientific Advice from the EMA, with positive results from this trial
expected to be sufficient for registration in the US and Europe.
Perifosine is also being explored in combination therapy and in
monotherapy in other cancer indications. Aeterna Zentaris holds
worldwide rights to perifosine except for Japan, Korea and MENA (Middle
East and North Africa) region, where licensing rights have been granted
to Yakult Honsha, Handok and Hikma Pharmaceuticals respectively.

About Aeterna Zentaris

Aeterna Zentaris is an oncology and endocrinology drug development
company currently investigating treatments for various unmet medical
needs. The Company’s pipeline encompasses compounds at all stages of
development, from drug discovery through to marketed products. For more
information please visit www.aezsinc.com.
 

 

SOURCE AETERNA ZENTARIS INC.


Source: PR Newswire